

IDNA

iShares Genomics Immunology and Healthcare ETF Analyst Report

IDNA tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering.

ESG Themes and Scores

5.3/10

ESG Rate

18.73%

Global Percentile

9.38%

Peer Percentile

Performance Data

| | IDNA | ETF Database Category Average | Factset Segment Average |
|---------------|---------|-------------------------------|-------------------------|
| 1 Month | -0.54% | 3.11% | 3.28% |
| 3 Month | 14.30% | 15.41% | 13.52% |
| YTD Return | 15.59% | 21.36% | 16.40% |
| 1 Year Return | 16.78% | 21.69% | 17.14% |
| 3 Year Return | 0.41% | 6.78% | 0.18% |
| 5 Year Return | -11.12% | 0.86% | -9.86% |

Top 5 Holdings

| Symbol | Holding | % Assets |
|--------|---------------------------------|----------|
| RVMD | Revolution Medicines, Inc. | 6.25% |
| CELC | Celcuity Inc. | 5.84% |
| REGN | Regeneron Pharmaceuticals, Inc. | 5.13% |
| GMAB | Genmab A/S | 4.81% |
| INCY | Incyte Corporation | 4.78% |

Vitals

| | |
|---------------|---|
| Issuer | BlackRock, Inc. |
| Brand | iShares |
| Structure | ETF |
| Expense Ratio | 0.47% |
| Inception | Jun 11, 2019 |
| Index Tracked | NYSE FactSet Global Genomics and Immuno Biopharma Index |

ETF Database Themes

| | |
|-------------------|---------------------------|
| Category | Health & Biotech Equities |
| Asset Class | Equity |
| Asset Class Size | Multi-Cap |
| Asset Class Style | Blend |
| Region (General) | North America |
| Region (Specific) | U.S. |

FactSet Classifications

| | |
|-----------|-------------------------------------|
| Segment | Equity: Global Genomic Advancements |
| Category | Sector |
| Focus | Theme |
| Niche | Genomic Advancements |
| Strategy | Vanilla |
| Weighting | Market Cap |

